Faculty details

Prof. Bart Staels
Picture
Prof. Bart Staels
Country France
Email bart.staels@pasteur-lille.fr
Institution Institut Pasteur and Université Lille Nord de France, Lille
Bio Bart Staels, PhD., is professor in the faculty of pharmacy at the University of Lille 2, Lille, France. Since January 1st, 2007, he has become director of the Inserm Unit UMR-S 545 and chairman of the Department of Atherosclerosis. He has been director of the new founded Inserm Unit UMR 1011 since January 1st, 2010 (AERES evaluation A+ and n° 1 of CSS4 Inserm) with laboratories (around 75 persons) on the campus of the Institut Pasteur de Lille, and the Research Pole of the University of Lille 2, Lille, France. Pr. Staels earned his doctorate at the Institute for Pharmaceutical Sciences, University of Leuven, Belgium. He completed postdoctoral work at the Metabolic Research Unit, University of California, San Francisco and was postdoctoral research fellow of the Reverse Cholesterol Transport/Atherosclerosis Project, BioAvenir, Vitry sur Seine, France. Pr. Staels is a member of learned societies such as the European Atherosclerosis Society, the International Atherosclerosis Societies (Distinguished Fellow), the Nouvelle Société Française d’Athérosclérose, the ALFEDIAM, the American Heart Association (Premium Professional Silver Heart Member), the American Diabetes Association and European Association for the Study of Diabetes. He is President of the Nouvelle Société Française d’Athérosclérose (NSFA) from 2009. Pr. Staels is also co-founder of the biotechnology company Genfit SA, and president of the Scientific Advisory Board. He is co-founder and board member of EGID (European Genomic Institute for Diabetes). The recipient of numerous grants, awards, and scientific prizes, Pr Staels has been awarded the Young Investigator Award of the European Atherosclerosis Society, the Bronze Medal of the CNRS and the Lifetime Achievement Award of the British Atherosclerosis Society, and the pharmaceutical “Barré” prize 2007 from the Faculté de Pharmacie of Montreal. Pr. Staels’ research focuses on molecular pharmacology of cardiovascular and metabolic diseases, including dyslipidemia and type 2 diabetes. He particularly studies the role of nuclear receptors (such as the PPARs, FXR, Rev-erbalpha and RORalpha in the control of inflammation and lipid and glucose homeostasis as well as the transcriptional mechanisms involved. Pr. Staels was among the first to identify a crucial role for the nuclear receptor PPARalpha in the control of lipid and glucose metabolism as well as cardiovascular function in humans. He elucidated the action mechanism of the fibrate class of drugs that are currently used in the treatment of lipid disorders and worked also on the action mechanism of the glitazones, a very recently developed class of anti-diabetic drugs. His work has identified the PPAR transcription factors as potential drug targets for the treatment of diabetes, dyslipidemia and cardiovascular disease, which contributed to the development of several novel therapeutic compounds, one of them is currently in phase IIb of clinical development. To date, Pr. Staels has published more than 300 original papers. He has also authored more than 160 review articles and contributed to several book chapters. He received the ISI citations award (citation number of 27169; h-index factor of 88 and average citation of 46/article). Based on the French 2007 Necker Institute dossier, Pr.Staels is among the 35 french researchers with the highest publication volume (2000-2005). Pr. Staels is also reviewer for numerous international journals and has been invited speaker at many prestigious international meetings, including the IAS, AHA, ADA and IDF. He contributed to the organization of congresses such as the “International Symposia on PPARs”, the NSFA annual congress and was chairman of a 2007 Keystone Symposium (“Metabolic Syndrome”). He is chairman of the 2012 Keystone Symposium on “Genetic and Molecular Basis of Obesity and Body Weight Regulation”.
Sessions
TUESDAY JUNE 28
15:45-16:15
YOUNG INVESTOR AWARD CEREMONY
C. Müller Hall
WEDNESDAY JUNE 29
11:00-12:30
Workshop:
NUCLEAR RECEPTORS AT THE CROSSROAD OF LIPID METABOLISM AND INFLAMMATION

Track: FROM THE VULNERABLE PLAQUE TO THE VULNERABLE PATIENT– CHALLENGES FOR TRANSLATIONAL MEDICINE
C. Müller Hall